Croatian Science Foundation (HRZZ), Croatian Agency for SMEs, Innovation and Investment (HAMAG-BICRO), and the Ministry of Science, Education and Youth (MZOM) organised the National Info Day of the Horizon Europe Programme - European Innovation Council (EIC). At the EIC Info Day held in Zagreb on 18 February 2026, Dora Adanić took part as a speaker in a discussion focused on the EIC Accelerator programme and its highly competitive evaluation process. During the session, she shared practical insights on what makes a proposal stand out, the importance of building a strong team alongside breakthrough technology, and how companies should prepare 6–12 months ahead of submission. She also addressed key topics such as risk management, scale-up strategy, competition, and the value of coaching and external feedback when developing a successful application. The discussion concluded with concrete advice for future applicants aiming to secure EIC Accelerator support.

From 19–21 November 2025, representatives of Genera Research Ltd. visited the Cleveland Clinic Foundation in Cleveland, Ohio, following an invitation from the Cleveland Clinic Innovations team. Cleveland Clinic is one of the world’s leading academic medical centers, internationally recognized for excellence in clinical care, biomedical research, innovation, and orthopaedic medicine. The visit provided an important opportunity to present OSTEOGROW-C, Genera’s Phase III biological drug candidate for the treatment of bone fracture non-unions, to the Department of Orthopaedics and Traumatology and to the Innovation Department. Discussions focused on Cleveland Clinic’s potential participation in the Phase III clinical trial and on defining future collaboration models. A dedicated lecture was delivered at the Musculoskeletal Research Center, where more than 50 orthopaedic surgeons and traumatologists attended the presentation online, demonstrating strong professional interest in the therapy. The visit marked a significant step in Genera’s US clinical expansion strategy and reinforced the importance of international partnerships in advancing innovative regenerative therapies.